Publicação
Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer
| dc.contributor.author | Barreto, Inês | |
| dc.contributor.author | Figueiredo, Sara | |
| dc.contributor.author | Tonin, Fernanda | |
| dc.contributor.author | Vilariça, Ana Sofia | |
| dc.contributor.author | Hasmucrai, Direndra | |
| dc.contributor.author | Alves, Paula | |
| dc.date.accessioned | 2024-04-02T11:28:00Z | |
| dc.date.available | 2024-04-02T11:28:00Z | |
| dc.date.issued | 2023-10 | |
| dc.description.abstract | Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), was recently introduced in several countries, including Portugal (reimbursement in 2021), as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating proto-oncogene epidermal growth factor receptor mutations (EGFRm), after showing significant efficacy and safety when used in patients with EGFR-T790M resistance mutations. However, despite advances in personalized target treatments in this field, challenges regarding patients’ journey (e.g., therapy selection criteria, EGFR-TKI optimal sequencing, treatment beyond second-line) still exist. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Barreto I, Figueiredo S, Tonin FS, Vilariça AS, Hasmucrai D, Alves P. Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer. Port J Card Thorac Vasc Surg. 2023;30(3):9-11. | pt_PT |
| dc.identifier.doi | 10.48729/pjctvs.381 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.21/17243 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Sociedade Portuguesa de Cirurgia Cárdio-Torácica e Vascular | pt_PT |
| dc.relation.publisherversion | https://pjctvs.com/index.php/journal/article/view/381 | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt_PT |
| dc.subject | Lung cancer | pt_PT |
| dc.subject | Non-small-cell lung cancer | pt_PT |
| dc.subject | EGFR mutation | pt_PT |
| dc.subject | Real-world data | pt_PT |
| dc.subject | Tyrosine kinase inhibitors | pt_PT |
| dc.title | Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 11 | pt_PT |
| oaire.citation.issue | 3 | pt_PT |
| oaire.citation.startPage | 9 | pt_PT |
| oaire.citation.title | Portuguese Journal of Cardiac Thoracic and Vascular Surgery | pt_PT |
| oaire.citation.volume | 30 | pt_PT |
| person.familyName | Tonin | |
| person.givenName | Fernanda | |
| person.identifier.ciencia-id | D01C-C700-9411 | |
| person.identifier.orcid | 0000-0003-4262-8608 | |
| person.identifier.rid | O-2050-2017 | |
| person.identifier.scopus-author-id | 56085115800 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | 61ded30e-ecec-4b3e-b953-2293e080ebdd | |
| relation.isAuthorOfPublication.latestForDiscovery | 61ded30e-ecec-4b3e-b953-2293e080ebdd |
Ficheiros
Principais
1 - 1 de 1
Miniatura indisponível
- Nome:
- Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer.pdf
- Tamanho:
- 410.88 KB
- Formato:
- Adobe Portable Document Format
Licença
1 - 1 de 1
Miniatura indisponível
- Nome:
- license.txt
- Tamanho:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descrição: